Sublingual Immunotherapy Linked to Clinical Benefits in HIV

This article originally appeared here.
Share this content:
Sublingual Immunotherapy Linked to Clinical Benefits in HIV
Sublingual Immunotherapy Linked to Clinical Benefits in HIV

TUESDAY, Aug. 4, 2015 (HealthDay News) -- For grass pollen-allergic HIV-positive patients treated with highly-active antiretroviral therapy (HAART), sublingual immunotherapy (SLIT) is associated with significant clinical benefits, according to a study published online July 30 in Allergy.

Enrico Iemoli, Ph.D., from the Sacco Hospital in Milan, and colleagues examined the safety and clinical effectiveness of SLIT in a group of grass pollen-allergic HIV-positive patients treated with HAART. The authors compared 13 patients receiving SLIT tablets and symptomatic therapy with nine receiving symptomatic therapy alone. Analysis of total combined score (TCS), sum of symptom-medication score, and a quality of life (QoL) questionnaire were used to evaluate clinical benefits.

The researchers found that SLIT-treated patients had significant improvement compared to controls in clinical efficiency data (TCS: P = 0.0001; QoL: P = 0.03). No significant alteration was seen in TCD4 cell counts or viral load in either group.

"Our preliminary data, in a small group of HIV-positive patients, show that not only [is] the SLIT therapy clinically effective but it is safe and does not change any immune-virological parameter," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Vit D Independently, Inversely Tied to Cholesterol in Children

Vit D Independently, Inversely Tied to Cholesterol in ...

Gene variants do not modify the associations of 25(OH)D with lipids

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Lower degree of susceptibility to ibalizumab for nine of 10 patients with virology failure, rebound

Weight Gain After Quitting Smoking May Up T2DM Risk

Weight Gain After Quitting Smoking May Up T2DM ...

But temporary increase in type 2 diabetes risk does not attenuate benefits on total, CVD mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »